Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction

Transplantation

Volumn 83, Issue 7, 2007, Pages 874-882

  Walker, Jennifer K ^a   Scholz, Lisa M ^a   Scheetz, Marc H ^a   Gallon, Lorenzo G ^a   Kaufman, Dixon B ^a   Rachwalski, Erik J ^a   Abecassis, Michael M ^a   Leventhal, Joseph R ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Alemtuzumab; Cytomegalovirus; Leukopenia; Renal transplantation; Valganciclovir

Indexed keywords

ALEMTUZUMAB; CLOTRIMAZOLE; COTRIMOXAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENTAMIDINE; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SEROLOGY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 34247561194     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000257923.69422.4d     Document Type: Article

References (28)

1. Watson CJE, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath-1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005; 5: 1347-1353.
2. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005; 5: 2539-2548.
3. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136: 754-760.
4. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 2005; 200: 505-515.
5. Ciancio G, Burke GW, Gaynor JJ, et al. Arandomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring. Transplantation 2005; 80: 457-465.
6. Hale G, Xia MQ, Tighe HP, et al. The campath-1 antigen (Cdw52). Tissue Antigens 1990; 35: 118-127.
7. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the Campath-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089-1096.
8. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
9. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657-2663.
10. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98: 773-778.
11. Malek SK, Obmann MA, Gotoff RA, et al. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81: 17-20.
12. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
13. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495-507.
14. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731-736.
15. Gabardi S, Magee CC, Baroletti SA, et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323-1330.
16. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
17. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
18. Czock D, Scholle C, Rasche FM, et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142-150.
19. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174.
20. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495-507.
21. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
22. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
23. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-2386.
24. Fauci AS, Dale DC, Balow JE. Glucocorticoid therapy: mechanism of action and clinical considerations. Ann Intern Med 1976; 84: 304-315.
25. Liles WC, Dale DC, Kiebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995; 86: 3181-3186.
26. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
27. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
28. Strippoli GF, Hodson EM, Jones C, Craig JC. Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139-145.